V. Valero

Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy

Abenaa M. Brewster, Gabriel N. Hortobágyi, Kristine Broglio et al. · JNCI Journal of the National Cancer Institute · 2008 · 333 citations · Full text

Medicine, Biostatistics, Oncology +17

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

Sang T. Kim, Yanshuo Chu, Mercy Misoi et al. · Nature Communications · 2022 · 116 citations · Full text

Life Sciences, Immunology, Oncology +17

Circulating tumor cells and bone metastases as detected by FDG–PET/CT in patients with metastatic breast cancer

Ugo De Giorgi, V. Valero, Eric Rohren et al. · Annals of Oncology · 2009 · 85 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors

Anthony W. Tolcher, Razelle Kurzrock, V. Valero et al. · Cancer Chemotherapy and Pharmacology · 2020 · 58 citations · Full text

Medicine, Oncology, Pharmacology +15

Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer

Chelsea G. Ratcliff, Cho Y. Lam, Banu Arun et al. · Psycho-Oncology · 2014 · 54 citations

Medicine, Oncology, Breast Oncology +16